Blog
Cite
Save
Email
Print
ShareScienceDaily (June 28, 2006) — Parkinson's, Alzheimer's, Lou Gehrig's disease and other brain disorders are among a growing list of maladies attributed to oxidative stress, the cell damage caused during metabolism when the oxygen in the body assumes ever more chemically reactive forms.
But the precise connection between oxidation and neurodegenerative diseases has eluded researchers. Now, a study by the Department of Energy's Pacific Northwest National Laboratory and UCLA's David Geffen School of Medicine reveals that damage is linked to a natural byproduct of oxidation called nitration.
"We looked at a healthy brain and found nitration of proteins that are implicated in neurodegenerative disease," said Colette Sacksteder, PNNL scientist and lead author of the study, published in the July issue of the journal Biochemistry (online Wed., June 28). PNNL scientist Wei-Jun Qian was co-lead author.
The results are from the most detailed proteomic analysis of a mammalian brain to date – that is, a survey of nearly 8,000 different, detectable proteins in the mouse brain. The research suggests that many neurodegenerative diseases leave a biochemical calling card, or biomarker, that could be used to predict the earliest stages of brain impairment. Many biomedical researchers believe that detecting disease states before symptoms occur is the key to reversing many as-yet-incurable diseases.
The biomarker is known as nitrotyrosine, made when an amino acid in the brain, tyrosine, is in the presence of an oxidative-stress molecule called peroxynitrate. The biomarker was found on 31 sites along 29 different proteins, half of which had been previously implicated in several of the neurodegenerative diseases.
"Our study certainly suggests that the sensitivity of certain proteins to peroxynitrite is an early contributor to neurodegeneration, but other factors may also be involved," said Diana Bigelow, PNNL staff scientist and the paper's corresponding author. "The next step, of explicitly looking at tissues with neurodegenerative disease, will test this hypothesis."
The study was made possible by a specially modified mass spectrometer at PNNL, housed at the W.R. Wiley Environmental Molecular Sciences Laboratory. The instrument, designed and operated by a group led by co-author and Richard D. Smith, a Battelle Fellow, separates and identifies proteins with unprecedented precision. Bigelow and colleagues supported the results with standard molecular biology techniques. The study was funded by the National Institutes of Health and PNNL.
Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Pacific Northwest National Laboratory, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
more 
